Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Navidea Biopharmaceuticals Inc (NYSE MKT LLC:NAVB)

0.71
Delayed Data
As of Dec 02
 -0.0131 / -1.81%
Today’s Change
0.26
Today|||52-Week Range
1.53
-46.62%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$110.6M

Company Description

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. The company operates through the following segments: Diagnostics, Therapeutics and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Contact Information

Navidea Biopharmaceuticals, Inc.
5600 Blazer Parkway
Dublin Ohio 43017-1367
P:(614) 793-7500
Investor Relations:
(617) 532-0624

Employees

Shareholders

Mutual fund holders4.41%
Other institutional14.49%
Individual stakeholders11.18%

Top Executives

Mike M. GoldbergPresident, Chief Executive Officer & Director
Jed Andrew LatkinChief Operating & Financial Officer
Frederick O. CopeChief Scientific Officer & Senior Vice President
David ColbornVice President-Clinical Operations
Michael TomblynChief Medical Officer & Senior Vice President